Article
Hematology
Purushoth Ethiraj, Binu Sasi, Kenneth N. Holder, An-Ping Lin, Zhijun Qiu, Carine Jaafar, Alia Elkhalili, Parth Desai, Annapurna Saksena, Jacob P. Ritter, Ricardo C. T. Aguiar
Summary: The study suggests that MYC expression is positively associated with vascular endothelial growth factor (VEGF) expression and angiogenesis in diffuse large B-cell lymphoma (DLBCL). Modulation of cyclic-AMP (cAMP) levels, which can be achieved with clinical grade PDE4 inhibitors, has anti-angiogenic activity in DLBCL.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Review
Oncology
Kenneth N. Huynh, Sriram Rao, Bradley Roth, Theodore Bryan, Dayantha M. Fernando, Farshid Dayyani, David Imagawa, Nadine Abi-Jaoudeh
Summary: Hypoxia-inducible factor 1 alpha (HIF-1a) is a transcription factor that regulates the cellular response to hypoxia and is upregulated in all types of solid tumor. Hepatocellular carcinoma (HCC) is a highly vascular and hypoxic tumor, and treatments like TACE and TAE can exacerbate hypoxia in HCC. Hypoxia-activated prodrugs (HAPs) have potential as a targeted treatment for hypoxic HCC, but more research is needed to understand their effects in combination with embolization.
Article
Biotechnology & Applied Microbiology
Chang Liu, Sijie Li, Xiaoxiao Zhang, Chunxiang Jin, Baofeng Zhao, Liying Li, Qing Robert Miao, Ying Jin, Zhimin Fan
Summary: NgBR plays a role in regulating metabolism and paclitaxel resistance in breast cancer, and may be a new therapeutic target for improving chemoresistance in ER-positive breast cancer.
CANCER GENE THERAPY
(2023)
Review
Biochemistry & Molecular Biology
Staci L. L. Haney, Sarah A. A. Holstein
Summary: Multiple myeloma (MM) is an incurable plasma cell malignancy. The isoprenoid biosynthetic pathway (IBP) is responsible for post-translational modification of proteins, and inhibitors targeting this pathway have shown anti-MM effects. Some IBP inhibitors have entered clinical trials, including nitrogenous bisphosphonates, statins, and farnesyltransferase inhibitors. Recent advances in the development of IBP inhibitors and their potential as anti-MM agents are discussed.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Lukas John, Maria Theresa Krauth, Klaus Podar, Marc-Steffen Raab
Summary: Multiple Myeloma is a cancer of plasma cells in the bone marrow. Pathway-directed therapy combined with personalized medicine can improve treatment outcomes. Targeting specific signaling pathways and conducting precision medicine trials may fundamentally change treatment strategies for Multiple Myeloma.
Review
Pharmacology & Pharmacy
Shuang Luo, Yu Jiang, Anfu Zheng, Yueshui Zhao, Xu Wu, Mingxing Li, Fukuan Du, Yu Chen, Shuai Deng, Meijuan Chen, Wanping Li, Xiaobing Li, Li Gu, Yuhong Sun, Zhangang Xiao, Jing Shen
Summary: Hypoxia-inducible factors (HIFs), central regulators in the adaptation of cells to low oxygen levels, are frequently overexpressed and activated in breast cancer. They influence various processes related to cancer development, such as glycolysis, angiogenesis, and metastasis, thus affecting the prognosis of breast cancer patients. Targeting HIFs specifically could potentially enhance the efficiency of cancer therapy. Additionally, drug delivery systems (DDSs) for HIF targeting, including liposomes, polymers, and nanoparticles, are being developed.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Cell Biology
Lu Gao, Weixian Chen, Lijun Li, Juanjuan Li, Wenyao Kongling, Yaoyang Zhang, Xueping Yang, Yanrong Zhao, Jie Bai, Fu Wang
Summary: Type H vessels play a role in osteogenesis and Epoxyeicostrioleic acids (EETs) contribute to vascular homeostasis. It is unclear whether increasing EETs with sEH inhibitor TPPU can enhance the coupling of angiogenesis and osteogenesis. In this study, TPPU was found to enhance osteogenic differentiation and promote bone growth and repair. Mechanistically, TPPU promoted cell proliferation and angiogenesis and increased the expression of certain factors involved in endothelial cell function. The results suggest that targeting EETs metabolic pathways can be a promising strategy for bone regeneration and repair.
CELL PROLIFERATION
(2023)
Article
Biochemistry & Molecular Biology
Jin-Woo Kim, Hyun-Ju An, HyunJeong Yeo, Yunhui Jeong, HyeonHae Lee, Jusung Lee, Kisik Nam, Jongheon Lee, Dong-Eun Shin, Soonchul Lee
Summary: Activation of the HIF-1α signaling pathway can protect intervertebral discs from degeneration and may serve as a potential therapeutic target in the future.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Daniela N. Petrusca, Patrick L. Mulcrone, David A. Macar, Ryan T. Bishop, Evgeny Berdyshev, Attaya Suvannasankha, Judith L. Anderson, Quanhong Sun, Philip E. Auron, Deborah L. Galson, G. David Roodman
Summary: This study identifies a novel mechanism by which GFI1 regulates the growth and survival of high risk multiple myeloma (MM) cells through modulation of sphingolipid metabolism. Regardless of p53 status, GFI1 increases intracellular levels of sphingosine-1-phosphate, stabilizing c-Myc and promoting MM cell viability. This finding suggests GFI1 as a potential therapeutic target for the treatment of MM, specifically in patients with non-functional p53.
Review
Oncology
Shigeki Ito, Tsuyoshi Sato, Takahiro Maeta
Summary: The SDF-1 alpha/CXCR4 axis plays crucial roles in multiple myeloma, affecting various physiological processes of tumor cells such as proliferation, survival, invasion, dissemination, and drug resistance. This review highlights the pleiotropic role of this axis and discusses potential targeted therapies in multiple myeloma.
Article
Oncology
Omar Faruq, Davidson Zhao, Mariusz Shrestha, Andrea Vecchione, Eldad Zacksenhaus, Hong Chang
Summary: High expression of MDM2 is associated with poor prognosis and drug resistance in human myeloma cell lines (HMCLs). MDM2 inhibition can sensitize resistant cells to anti-myeloma drugs and induce apoptosis. The study demonstrates the oncogenic regulatory loop between MDM2 and c-Myc, and suggests targeting the MDM2/c-Myc axis as a potential therapeutic strategy for refractory/relapsed MM.
Article
Oncology
Libin Jiang, Yingxia Li, Yixin He, Dapeng Wei, Lvyin Yan, Hongtao Wen
Summary: IGF2BP3 regulates hypoxia-induced cell migration and angiogenesis in stomach cancer by directly binding to HIF1A mRNA and positively regulating its expression.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Baoshen Wang, Chunyan Zhang, Dongmei Chu, Xiaofang Ma, Tian Yu, Xiaozhi Liu, Changqing Hu
Summary: The study confirmed that AS-IV promotes angiogenesis in hypoxic conditions by affecting the SUMO modification of HIF-1α. Rapid attenuation and delayed compensation of SUMO1 activity led to fluctuations in HIF-1α levels, while SUMO1 overexpression stabilized HIF-1α and improved blood vessel morphology.
MOLECULAR MEDICINE REPORTS
(2021)
Review
Oncology
Sho Ikeda, Hiroyuki Tagawa
Summary: Multiple myeloma is a refractory plasma cell tumor in which IRF4 and MYC play crucial roles in oncogenesis, while hypoxic response in the bone marrow microenvironment contributes to treatment resistance. Combination therapeutic strategies targeting both IRF4-MYC and HIF may be important for achieving deep remission in MM.
Article
Medicine, Research & Experimental
Qinglan Wang, Feng Zhang, Yang Lei, Ping Liu, Chenghai Liu, Yanyan Tao
Summary: The study investigated the effects and mechanism of miR-322/424 in liver fibrosis, revealing that miR-322/424 plays a crucial role in targeting Cullin2 and enhancing HIF-1 alpha-mediated hepatic angiogenesis. The results showed that miR-322/424 levels were increased in liver cirrhosis patients and animal models, with its agonist exacerbating fibrosis while the antagonist had the opposite effect.
Article
Oncology
Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, Judith Lind, Jose Manuel Garcia-Manteiga, Eugenio Morelli, Qinyue Jiang, Anja Seckinger, Dirk Hose, Hartmut Goldschmidt, Andreas Stadlbauer, Chunyan Sun, Heng Mei, Martin Pecherstorfer, Latifa Bakiri, Erwin F. Wagner, Giovanni Tonon, Martin Sattler, Yu Hu, Pierfrancesco Tassone, Dirk Jaeger, Klaus Podar
Summary: This study demonstrates a significant correlation between JunB and angiogenic factors in MM, independent of hypoxia. JunB plays a dual role as a mediator of MM cell survival, proliferation, drug resistance, and also promotes angiogenesis in the BM microenvironment. These findings suggest targeting JunB as a potential strategy in MM therapy.
Correction
Oncology
Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, Judith Lind, Jose Manuel Garcia-Manteiga, Eugenio Morelli, Qinyue Jiang, Anja Seckinger, Dirk Hose, Hartmut Goldschmidt, Andreas Stadlbauer, Chunyan Sun, Heng Mei, Martin Pecherstorfer, Latifa Bakiri, Erwin F. Wagner, Giovanni Tonon, Martin Sattler, Yu Hu, Pierfrancesco Tassone, Dirk Jaeger, Klaus Podar
Meeting Abstract
Hematology
Judith Lind, Sonia Vallet, Karoline Kollmann, Osman Aksoy, Vincent Sunder-Plassmann, Fengjuan Fan, Elisabeth Zwickl-Traxler, Dagmar Stoiber, Latifa Bakiri, Erwin F. Wagner, Martin Sattler, Martin Percherstorfer, Klaus Podar
Meeting Abstract
Hematology
Osman Aksoy, Judith Lind, Vincent Sunder-Plassmann, Martin Percherstorfer, Sonia Vallet, Klaus Podar
Review
Oncology
Samantha Pozzi, Alessia Bari, Martin Pecherstorfer, Sonia Vallet
Summary: RRMM patients face increased toxicity risks due to prolonged exposure to multiple drugs. Preserving quality of life is crucial, and supportive care plays a key role in managing disease- and treatment-related complications. Novel strategies, such as anabolic bone agents and ALK inhibitors, are being investigated alongside established supportive therapies like erythropoietin-stimulating agents and bisphosphonates.
Review
Oncology
Oronza A. Botrugno, Giovanni Tonon
Summary: Genomic instability is a major factor in drug resistance in cancers, including multiple myeloma; Replicative stress plays a key role in fueling genomic instability; Multiple myeloma cells rely on the ATR protein to cope with DNA damage.
Review
Oncology
Klaus Podar, Xavier Leleu
Summary: Collaborative translational studies have enhanced our knowledge of multiple myeloma pathophysiology over the past two decades, but it remains an incurable disease requiring ongoing research to improve patient outcomes. Exciting therapeutic progress, including new drug approvals and emerging treatments in 2020/2021, continues to advance in the field of multiple myeloma.
Article
Oncology
Michael Leisch, Michael Pfeilstoecker, Reinhard Stauder, Sonja Heibl, Heinz Sill, Michael Girschikofsky, Margarete Stampfl-Mattersberger, Christoph Tinchon, Bernd Hartmann, Andreas Petzer, Martin Schreder, David Kiesl, Sonia Vallet, Alexander Egle, Thomas Melchardt, Gudrun Piringer, Armin Zebisch, Sigrid Machherndl-Spandl, Dominik Wolf, Felix Keil, Manuel Drost, Richard Greil, Lisa Pleyer
Summary: Azacitidine is the only drug proven to prolong overall survival and is recommended for patients with certain types of leukemia. Adverse events during treatment with azacitidine were analyzed, and it was found that hematologic adverse events occurred at a similar rate compared to clinical trials, but gastrointestinal toxicities were less commonly reported.
Review
Pharmacology & Pharmacy
Vincent Sunder-Plassmann, Osman Aksoy, Judith Lind, Martin Pecherstorfer, Sonia Vallet, Klaus Podar
Summary: This article summarizes the recent advances in MM immunotherapies presented at the 2021 Annual Meeting of the American Society of Hematology and provides an outlook on ongoing research efforts aiming to improve efficacy and reduce toxicity.
EXPERT OPINION ON PHARMACOTHERAPY
(2022)
Article
Cell Biology
Piera Tocci, Celia Roman, Rosanna Sestito, Valeriana Di Castro, Andrea Sacconi, Ivan Molineris, Francesca Paolini, Mariantonia Carosi, Giovanni Tonon, Giovanni Blandino, Anna Bagnato
Summary: PARP inhibitors have changed the treatment paradigm of HG-SOC, but their efficacy is limited in patients with high TP53 mutation rates. The overexpression of the ET-1/ET1R axis in HG-SOC is associated with poor prognosis and inhibits the DNA damage response induced by PARP inhibitors. The ET-1R antagonist macitentan, in combination with olaparib, shows promising results in suppressing metastatic progression in HG-SOC patient-derived xenografts.
CELL DEATH & DISEASE
(2023)
Article
Oncology
Stella Rosa Maria Wirth, Klaus Podar, Martin Pecherstorfer, Philipp Wohlfarth, Ulrich Jaeger, Josef Singer
Summary: Patients with B-cell malignancies show improved antibody production after the third vaccination against SARS-CoV-2. However, those under active treatment with anti-CD19 CAR T-cells or anti-CD20 monoclonal antibodies face greater difficulties in developing neutralizing antibodies. Future studies with larger cohorts are needed to further understand the effective vaccination scheme for high-risk hematological patients.
Article
Hematology
Lisa Pleyer, Marc Vaisband, Manuel Drost, Michael Pfeilstoecker, Reinhard Stauder, Sonja Heibl, Heinz Sill, Michael Girschikofsky, Margarete Stampfl-Mattersberger, Angelika Pichler, Bernd Hartmann, Andreas Petzer, Martin Schreder, Clemens A. Schmitt, Sonia Vallet, Thomas Melchardt, Armin Zebisch, Petra Pichler, Nadja Zaborsky, Sigrid Machherndl-Spandl, Dominik Wolf, Felix Keil, Jan Hasenauer, Julian Larcher-Senn, Richard Greil
Summary: The current gold standard of response assessment in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) is morphologic complete remission (CR) and CR with incomplete count recovery (CRi), both of which require an invasive BM evaluation. A new response type termed peripheral blood complete remission (PB-CR) is defined and validated in this study, which can be determined from the differential blood count and clinical parameters without necessitating a BM assessment.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Urology & Nephrology
David D'Andrea, Shahrokh F. Shariat, Francesco Soria, Andrea Mari, Laura S. Mertens, Ettore Di Trapani, Diego M. Carrion, Benjamin Pradere, Renate Pichler, Ronan Filippot, Guillaume Grisay, Francesco Del Giudice, Ekaterina Laukhtina, David Paulnsteiner, Wojciech Krajewski, Sonia Vallet, Martina Maggi, Ettore De Berardinis, Mario Alvarez-Maestro, Stephan Bronimann, Fabrizio Di Maida, Bas W. G. van Rhijn, Kees Hendricksen, Marco Moschini
Summary: Patients with primary MIBC have better pathologic response rates to NAC in comparison to patients with secondary MIBC. Chemoresistance might be related to the different genomic profile of primary versus secondary MIBC.
EUROPEAN UROLOGY OPEN SCIENCE
(2022)
Article
Oncology
Klaus-Peter Dieckmann, Tomas Pokrivcak, Lajos Geczi, David Niehaus, Inken Dralle-Filiz, Cord Matthies, Tamas Dienes, Stefanie Zschaebitz, Pia Paffenholz, Tanja Gschliesser, Renate Pichler, Michal Mego, Pia Bader, Friedemann Zengerling, Julia Heinzelbecker, Philipp Krausewitz, Susanne Krege, Gaetano Aurilio, Cem Aksoy, Marcus Hentrich, Christoph Seidel, Peter Toerzsoek, Tim Nestler, Matthaeus Majewski, Andreas Hiester, Tomas Buchler, Sonia Vallet, Hana Studentova, Sandra Schoenburg, Dora Niedersuess-Beke, Julia Ring, Emanuela Trenti, Axel Heidenreich, Christian Wuelfing, Hendrik Isbarn, Uwe Pichlmeier, Martin Pichler
Summary: The 1xBEP regimen is a safe treatment for patients with CS1 NSGCT, with a low relapse rate and a high cure rate for relapses.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Article
Oncology
Josef Singer, Nguyen-Son Le, Daniel Mattes, Valerie Klamminger, Klaus Hackner, Nicole Kolinsky, Michaela Scherb, Peter Errhalt, Gudrun Kreye, Martin Pecherstorfer, Sonia Vallet, Klaus Podar
Summary: Vaccination is the primary public health strategy to combat the COVID-19 pandemic, with solid tumor and hematologic patients being at higher risk of severe complications. Data on immune responses to COVID-19 vaccines in these patients are scarce. Complete vaccination is a valuable predictor for high anti-SARS-CoV-2 antibody responses in these vulnerable patient groups.